Sunday, July 6, 2025
Khmer Daily Cambodia News
34 °c
Phnom Penh
  • LATEST
  • CAMBODIA
  • ASIA
    • JAPAN
    • SOUTH KOREA
    • TAIWAN
  • WORLD
    • CHINA
    • RUSSIA
  • BUSINESS CAMBODIA
  • TECHNOLOGY
No Result
View All Result
  • LATEST
  • CAMBODIA
  • ASIA
    • JAPAN
    • SOUTH KOREA
    • TAIWAN
  • WORLD
    • CHINA
    • RUSSIA
  • BUSINESS CAMBODIA
  • TECHNOLOGY
No Result
View All Result
The Khmer Daily
No Result
View All Result
Home World

AstraZeneca antibody cocktail study shows success treating Covid-19

October 18, 2021
in Health, Lifestyle, Science, World
0
AstraZeneca antibody cocktail study shows success treating Covid-19
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter

AstraZeneca’s antibody cocktail against Covid-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.

The drug, a combination of two antibodies called AZD7442, reduced the risk of severe Covid-19 or death by 50 per cent in non-hospitalised patients who have had symptoms for seven days or less, the Anglo-Swedish drugmaker said on Monday.

The risk reduction was even better in patients who started therapy within just five days of initial symptoms, but AstraZeneca joins an already crowded field of medicines that were shown to prevent deterioration in patients with mild disease when given soon after diagnosis.

AstraZeneca executive Mene Pangalos said in a media call that the treatment results would mainly underscore the potential future use as a non-vaccine prevention.

“If and when this is approved it will be used in the treatment setting as well. But the real differentiator for this antibody is going to be in the prophylactic setting,” he said.

Similar therapies made with a class of drugs called monoclonal antibodies are being developed by Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir.

These therapies are approved for emergency use in the United States for treating mild to moderate Covid-19.

Regeneron’s therapy showed 72 per cent protection against symptomatic infection in the first week, and 93 per cent after that.

AstraZeneca said it is submitting the new treatment data on AZD7442 to global health regulators.

The trial took place across 13 countries and involved more than 900 adult participants, 90 per cent of whom suffered from conditions that made the particularly vulnerable to Covid-19, such as cancer and diabetes.

One half receiving AZD7442 and the rest a placebo. Full trial results will be submitted for publication in a peer reviewed journal, AstraZeneca said.

AZD7442 contains laboratory made antibodies designed to linger in the body for months to contain the virus in case of an infection.

A vaccine, in contrast, relies on an intact immune system to develop targeted antibodies and infection-fighting cells.

While Monday’s results cover the use of AZD7442 in non-hospitalised patients, a separate trial is also studying its use as a treatment for hospitalised Covid-19 patients.

This article was first published in Asia One . All contents and images are copyright to their respective owners and sources.

Tags: #coronavirus#COVID-19#studyAstraZenecaUnited States
Previous Post

WHO group backs third Covid-19 shot for elderly vaccinated with Sinovac or Sinopharm

Next Post

mRNA booster generates stronger antibody response after J&J shot: Report

Related Posts

Neak Poan Temple is a destination for tourists to visit and take beautiful pictures

Neak Poan Temple is a destination for tourists to visit and take beautiful pictures

by Khmer Times
July 3, 2023
0
104

Neak Poan Temple is one of the most attractive tourist destinations among the ancient temples, which is located along the...

Italy to pass ‘right to be forgotten’ law for cancer survivors

Italy to pass ‘right to be forgotten’ law for cancer survivors

by AsiaOne
June 15, 2023
0
25

ROME — Italy will pass a law on the "right to be forgotten" (RTBF) for cancer survivors, Prime Minister Giorgia Meloni...

Bill Gates in China: Microsoft co-founder to meet Xi Jinping

Bill Gates in China: Microsoft co-founder to meet Xi Jinping

by AsiaOne
June 15, 2023
0
39

HONG KONG — Bill Gates, Microsoft Corp's co-founder, is set to meet Chinese President Xi Jinping on Friday (June 16) during his...

Most Popular

New dairy farm in Cambodia, Kirisu, goes into fresh milk production operated by Khmer Fresh Milk

New dairy farm in Cambodia, Kirisu, goes into fresh milk production operated by Khmer Fresh Milk

July 17, 2020
506
Cambodia rice production losses caused by droughts about $100 million

Cambodia rice production losses caused by droughts about $100 million

October 1, 2021
16
Is this Japan’s weirdest mascot? Meet Hokkaido’s Zushihocky, part rice, part clam

Is this Japan’s weirdest mascot? Meet Hokkaido’s Zushihocky, part rice, part clam

May 27, 2020
38
Neak Poan Temple is a destination for tourists to visit and take beautiful pictures

Neak Poan Temple is a destination for tourists to visit and take beautiful pictures

July 3, 2023
104
Waste-to-energy plans in Cambodia on hold for time being

Waste-to-energy plans in Cambodia on hold for time being

November 11, 2020
31
Four Companies team-up to turn Sihanoukville into a Fintech hub in Cambodia

Four Companies team-up to turn Sihanoukville into a Fintech hub in Cambodia

December 2, 2021
33

© 2020 By Khmer Daily News

No Result
View All Result
  • Home
  • Latest
  • Cambodia
  • ASIA
  • World
  • Business
  • Tech

© 2019 The Khmer Daily.

error: Content is protected !!